Time to Stop Using Ineffective Covid-19 Drugs

Karim, Salim S. Abdool; Devnarain, Nikita

doi:10.1056/nejme2209017

Cited by 22 publications

(19 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While early outpatient RCTs, such as TOGETHER and STOP COVID, have found significant benefits associated with fluvoxamine in terms of reduced deterioration and hospitalization [ 10 , 11 ], more recent trials have found no such effects [ 12 , 13 ]. A commentary in response to the latest COVID-OUT trial had even concluded that fluvoxamine should not be prescribed due to a lack of benefits [ 14 ]. It is possible that different dosing regimens used in the RCTs are implicated in this controversy, with earlier RCTs using higher doses of fluvoxamine compared to newer RCTs [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis

Deng

Rayner

Ramaraju

et al. 2023

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis

Deng

Rayner

Ramaraju

et al. 2023

Clinical Microbiology and Infection

View full text Add to dashboard Cite

“…Several in silico studies [ 1 ] have found that the macrocyclic lactone ivermectin (IVM) binds with high affinity to subdomains on SARS-CoV-2 spike protein, including several glycosylated binding sites [ 43 ]. IVM achieved Nobel-prize-honored distinction for success against global parasitic scourges [ 44 ] but is of disputed efficacy in the treatment of COVID-19, as indicated, for example, by the disparity in the conclusions of this editorial [ 45 ] and its key cited meta-analysis [ 46 ].…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects

Boschi

Scheim²,

Bancod

et al. 2022

IJMS

View full text Add to dashboard Cite

Experimental findings for SARS-CoV-2 related to the glycan biochemistry of coronaviruses indicate that attachments from spike protein to glycoconjugates on the surfaces of red blood cells (RBCs), other blood cells and endothelial cells are key to the infectivity and morbidity of COVID-19. To provide further insight into these glycan attachments and their potential clinical relevance, the classic hemagglutination (HA) assay was applied using spike protein from the Wuhan, Alpha, Delta and Omicron B.1.1.529 lineages of SARS-CoV-2 mixed with human RBCs. The electrostatic potential of the central region of spike protein from these four lineages was studied through molecular modeling simulations. Inhibition of spike protein-induced HA was tested using the macrocyclic lactone ivermectin (IVM), which is indicated to bind strongly to SARS-CoV-2 spike protein glycan sites. The results of these experiments were, first, that spike protein from these four lineages of SARS-CoV-2 induced HA. Omicron induced HA at a significantly lower threshold concentration of spike protein than the three prior lineages and was much more electropositive on its central spike protein region. IVM blocked HA when added to RBCs prior to spike protein and reversed HA when added afterward. These results validate and extend prior findings on the role of glycan bindings of viral spike protein in COVID-19. They furthermore suggest therapeutic options using competitive glycan-binding agents such as IVM and may help elucidate rare serious adverse effects (AEs) associated with COVID-19 mRNA vaccines, which use spike protein as the generated antigen.

show abstract

“…However, for this overwhelming pandemic, “there aren’t always right answers, but some answers are wrong”, as reported by the American Board of Internal Medicine [ 11 ] regarding the promotion of misinformation by physicians. For instance, the experience taught us that some drugs first chosen for COVID-19 treatment have been demonstrated to produce scarce or even self-defeating effects, receiving WHO negative recommendations [ 12 ]. In this review, we aimed to report the most-used drugs, summarized in Table 1 , to treat COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Drugs for COVID-19: An Update

et al. 2022

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the seventh known human coronavirus, and it was identified in Wuhan, Hubei province, China, in 2020. It caused the highly contagious disease called coronavirus disease 2019 (COVID-19), declared a global pandemic by the World Health Organization (WHO) on 11 March 2020. A great number of studies in the search of new therapies and vaccines have been carried out in these three long years, producing a series of successes; however, the need for more effective vaccines, therapies and other solutions is still being pursued. This review represents a tracking shot of the current pharmacological therapies used for the treatment of COVID-19.

show abstract

Time to Stop Using Ineffective Covid-19 Drugs

Cited by 22 publications

References 9 publications

Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis

Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis

SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects

Drugs for COVID-19: An Update

Contact Info

Product

Resources

About